View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson

Still waiting for growth to return

Negative organic growth in both Healthcare & Lab. '24e-'26e adj. EBITDA down 7.8-12.8%. BUY maintained, TP down to SEK 10 (17).

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Philip Ekengren
  • Sten Gustafsson

Headwinds still on the cards

Q2’24 due 18 July. Tot. sales growth of +19% in Q2'24e, with -24% organic. TP down to SEK 17 (19), BUY reiterated with case intact.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch